User profiles for M. Lubberink

Mark Lubberink

- Verified email at radiol.uu.se - Cited by 12321

Max Lubberink

- Verified email at wur.nl - Cited by 108

[HTML][HTML] Quantification, improvement, and harmonization of small lesion detection with state-of-the-art PET

…, R Boellaard, JA van Dalen, M Lubberink… - European journal of …, 2017 - Springer
In recent years, there have been multiple advances in positron emission tomography/computed
tomography (PET/CT) that improve cancer imaging. The present generation of PET/CT …

[HTML][HTML] Clinical quantitative cardiac imaging for the assessment of myocardial ischaemia

…, S Nekolla, P Knaapen, M Lubberink… - Nature Reviews …, 2020 - nature.com
Cardiac imaging has a pivotal role in the prevention, diagnosis and treatment of ischaemic
heart disease. SPECT is most commonly used for clinical myocardial perfusion imaging, …

[HTML][HTML] Biocatalytic amide bond formation

M Lubberink, W Finnigan, SL Flitsch - Green Chemistry, 2023 - pubs.rsc.org
Amide bonds occur in over half of target compounds in medicinal chemistry patents, making
amide bond formation the most commonly performed reaction in the pharmaceutical industry…

[PDF][PDF] Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs

AAM Van der Veldt, M Lubberink, I Bahce, M Walraven… - Cancer cell, 2012 - cell.com
Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical
benefit in cancer patients. It is assumed that anti-angiogenic drugs, such as bevacizumab, …

Blood–brain barrier P-glycoprotein function in Alzheimer's disease

DME van Assema, M Lubberink, M Bauer… - Brain, 2012 - academic.oup.com
A major pathological hallmark of Alzheimer's disease is accumulation of amyloid-β in senile
plaques in the brain. Evidence is accumulating that decreased clearance of amyloid-β from …

Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission …

…, HJ Lamb, HWAM de Jong, M Lubberink… - Journal of the American …, 2009 - jacc.org
Objectives : This study was designed to evaluate myocardial substrate and high-energy
phosphate (HEP) metabolism in asymptomatic men with well-controlled, uncomplicated type 2 …

Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment

…, A Sundin, H Lundqvist, M Lubberink - Journal of Nuclear …, 2013 - Soc Nuclear Med
The organs at risk in radionuclide therapy with 177 Lu-octreotate are the bone marrow and
the kidneys. The primary aim of this study was to develop an individualized dosimetry …

Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate …

…, LJ Rijzewijk, HWAM de Jong, HJ Lamb, M Lubberink… - Circulation, 2009 - Am Heart Assoc
Background— Cardiac disease is the leading cause of mortality in type 2 diabetes mellitus (T2DM).
Pioglitazone has been associated with improved cardiac outcome but also with an …

First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule

…, V Tolmachev, G Åström, M Lubberink… - Journal of nuclear …, 2014 - Soc Nuclear Med
The expression status of human epidermal growth factor receptor type 2 (HER2) predicts
the response of HER2-targeted therapy in breast cancer. ABY-025 is a small reengineered …

[HTML][HTML] Measuring HER2-receptor expression in metastatic breast cancer using [68Ga] ABY-025 Affibody PET/CT

…, V Tolmachev, A Orlova, M Sandström, M Lubberink… - Theranostics, 2016 - ncbi.nlm.nih.gov
Purpose: Positron Emission Tomography (PET) imaging of HER2 expression could potentially
be used to select patients for HER2-targed therapy, predict response based on uptake …